Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: A phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR)

Anti-Cancer Drugs

Volumn 15, Issue 1, 2004, Pages 15-22

  Mross, Klaus ^a   Scheulen, Max E ^b   Licht, Thomas ^c   Unger, Clemens ^a   Richly, Heike ^b   Stern, Angelika C ^d   Kutz, Klaus ^e   Camboni, Maria G ^f   Barbieri, Paola ^f   Verdi, Elena ^f   Vincenzi, Beatrice ^f   Bernareggi, Alberto ^f  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d Hesperion Ltd   (Switzerland)

^e AccelPharm   (Switzerland)

^f Novuspharma SpA   (Italy)

Author keywords

Advanced solid tumor; Aza anthrapyrazole; BBR 3576; Central European Society of Anticancer Drug Research; Phase I

Indexed keywords

5 [[2 (DIMETHYLAMINO)ETHYL]AMINO] 2 [2 [(2 HYDROXYETHYL)AMINO]ETHYL]INDAZOLO[4,3 GH]ISOQUINOLIN 6(2H) ONE; ANTINEOPLASTIC AGENT; PYRAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANGINA PECTORIS; ANOREXIA; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG URINE LEVEL; DRY SKIN; DYSPEPSIA; DYSPHAGIA; DYSURIA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HUMAN; LEUKOPENIA; LUNG INFECTION; LYMPHOCYTOPENIA; MALE; MASTALGIA; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PLASMA CLEARANCE; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; SOLID TUMOR; STOMATITIS; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; INFUSION PUMPS; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MOLECULAR STRUCTURE; NEOPLASMS; NEUTROPENIA; PYRAZOLES; STOMATITIS;

EID: 2442594109     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200401000-00003     Document Type: Article

References (23)

1. Mross K. Klinische und pharmakologische Untersuchungen zur Pharmakokinetik, Metabolisierung, Pharmakodynamik und Toxizität von Anthrazyklinen. München: Zuckschwerdt; 1994.
2. Bachur N, Gorden S, Gee M. Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol 1977; 13:901-907.
3. von Hoff D, Layard M, Basa P, Davis H, von Hoff A, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710-717.
4. Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Vittrup Jensen B, et al. Epirubicin cardiotoxicity: an analysis of the 469 patients with metastatic breast cancer. J Clin Oncol 1998; 16:3502-3508.
5. Giordano SH, Booser DJ, Murray JL, Ibrahim NK, Rahman ZU, Valero V, et al. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res 2002; 8:3360-3368.
6. Herman EH, Ferrans VJ, Young RSK, Hamlin RL. Effect of treatment with ICRF-187 on the total cumulative dose of doxorubicin by beagle dogs. Cancer Res 1988; 48:6918-6925.
7. Menta E, Di Domenico R, Oliva A, Spinelli S, Beggiolin G, Pezzoni G, et al. Design, synthesis and antitumor evaluation of 9-aza-anthrapyrazoles. Proc Am Ass Cancer Res 1996; 87:abstr 2015.
8. Beggiolin G, Pezzoni G, Torriani D, Ruggeri F, Randisi E, De Giorgi M, et al. 9-Aza-anthrapyrazoles: new agents endowed with 'in vivo' antitumor activity. Proc Am Ass Cancer Res 1996; 87:abstr 2663.
9. Cavalletti E, Grippa L, Bellini O, Menta E, Cavagnoli R, Delbó D. 9-Aza-anthrapyrazoles devoid of cardiotoxic effects. Proc Am Ass Cancer Res 1996; 87:abstr 2662.
10. Therasse P, Arbruck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
11. Guyton AC (editor). Textbook of Medical Physiology. Philadelphia, PA: Saunders; 1966, p. 279.
12. Mross K. New anthracycline derivatives: what for? Eur J Cancer 1991; 27:1542-1544.
13. Bernard-Marty C, Mano M, Paesmans M, Accettura C, Munoz-Bemeo R, Richard T, et al. Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients. Ann Oncol 2003; 14:693-698.
14. Reszka K, Kolodziejczyk P, Hartley JA, Wilson WD, Lown JW. Molecular pharmacology of anthracenedione-based anticancer agents. In: Lown JW (editor): Anthracycline and Anthracenedione-based Anticancer Agents. Amsterdam: Elsevier; 1988, pp. 401-434.
15. Ehninger G, Schuler U, Proksch B, Zeller KP, Blanz J. Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet 2000; 18:365-380.
16. Faivre S, Raymond E, Boige V, Gatinau M, Buthaut X, Rixe O, et al. A phase I and clinical pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin Cancer Res 2001; 7:43-50.
17. Dawson LK, Jodrell DI, Bowman A, Rye R, Byrne B, Bernareggi A, et al. A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur J Cancer 2000; 36:2353-2350.
18. Behringer DM, Engelhardt R, Hofheinz RD, Hochhaus A, Herrmann R, Stern A, et al. Phase I dose escalation study on the tolerability and activity of BBR 3438 in patients with advanced solid tumors. Ann Oncol 2002; 13(suppl 5):23 (abstr 82P).
19. Droz JP, Brune D, Ricci S, Beuzeboc P, Chevreau C, Culine S, et al. Phase II study on the activity and tolerability of BBR 3576 given to patients with advanced hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 2003; 22:abstr 1670.
20. Beggiolin G, Crippa L, Menta E, Manzotti C, Cavalletti E, Pezzoni G et al. BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori 2001; 87:407-416.
21. Borchmann P, Schnell R, Knipphertz R, Staak JO, Camboni GM, Bernareggi A, et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann Oncol 2001; 12:661-667.
22. Mitoxantrone-Novantrone®. Prescribing information. Immunex, Seattle, WA.
23. Simon R, Freidlin B, Rubinstein L, Arbruck SG, Collins J, Cristian MC. Accelerated titration design for phase I clinical trial in oncology. J Natl Cancer Inst 1997; 15:1138-1147.